UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): July 9, 2021 
 
AzurRx BioPharma, Inc.
(Exact name of registrant as specified in its charter) 
 
 
 
 
 
Delaware
 
001-37853
 
46-4993860
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

777 Yamato Road, Suite 502
Boca Raton, Florida
 
33431
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (561) 589-7020
 
Not Applicable
 (Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
AZRX
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company [X]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 

 
 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On July 9, 2021, the Board of Directors (the “Board”) of AzurRx BioPharma, Inc. (the “Company”) approved an increase in the annual base salary of James Pennington, the Company’s Chief Medical Officer, from $260,000 to $425,000 per year, effective July 1, 2021, plus an additional one-time salary payment of $27,500. The Board also approved an award of 100,000 options (the “Options”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The Options were granted in accordance with the terms of the Company’s 2020 Omnibus Equity Incentive Plan, as amended and restated. The Options have an exercise price of $0.75, which is the closing price of the Common Stock on July 9, 2021, and will vest in 36 equal monthly installments over three years beginning on the date of grant.
 
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
July 9, 2021
AzurRx BioPharma, Inc.
 
By:       /s/ Daniel Schneiderman
Name:  Daniel Schneiderman
Title:    Chief Financial Officer
 
 
 
 
 
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more AzurRx BioPharma Charts.
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more AzurRx BioPharma Charts.